TrialLeukemia2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
F J Giles et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
50 papers cite it
this paperpooled ittrialcites it